[go: up one dir, main page]

WO2002064148A3 - Oral formulations containing mucopolysaccharide for small intestine delivery and their use in the treatment circulatory disorders - Google Patents

Oral formulations containing mucopolysaccharide for small intestine delivery and their use in the treatment circulatory disorders Download PDF

Info

Publication number
WO2002064148A3
WO2002064148A3 PCT/JP2002/001299 JP0201299W WO02064148A3 WO 2002064148 A3 WO2002064148 A3 WO 2002064148A3 JP 0201299 W JP0201299 W JP 0201299W WO 02064148 A3 WO02064148 A3 WO 02064148A3
Authority
WO
WIPO (PCT)
Prior art keywords
mucopolysaccharide
small intestine
formulations containing
oral formulations
circulatory disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2002/001299
Other languages
French (fr)
Other versions
WO2002064148A2 (en
Inventor
Kanji Takada
Akihiro Matsuura
Saori Mori
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shimizu Pharmaceutical Co Ltd
Original Assignee
Shimizu Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shimizu Pharmaceutical Co Ltd filed Critical Shimizu Pharmaceutical Co Ltd
Priority to JP2002563941A priority Critical patent/JP2004525110A/en
Priority to KR10-2003-7010649A priority patent/KR20040018333A/en
Priority to EP02712385A priority patent/EP1390048A2/en
Priority to CA002438707A priority patent/CA2438707A1/en
Publication of WO2002064148A2 publication Critical patent/WO2002064148A2/en
Publication of WO2002064148A3 publication Critical patent/WO2002064148A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

An oral administrable enteric formulation of mucopolysaccharide is provided by using an absorption enhancer for mucopolysaccharide comprising of fatty acid having 6 to 14 carbon atoms or salt, ester and amide derivative thereof; steroid carboxylic acid, or salt, ester and amide derivative thereof; and aliphatic poly-basic acid, or salt, ester and amide derivative thereof; or mixture thereof. Said mucopolysaccharide has been only administered by the injection formulations, and the effective blood concentration of said mucopolysaccharide has not been obtained by oral administration.
PCT/JP2002/001299 2001-02-16 2002-02-15 Oral formulations containing mucopolysaccharide for small intestine delivery and their use in the treatment circulatory disorders Ceased WO2002064148A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2002563941A JP2004525110A (en) 2001-02-16 2002-02-15 Mucopolysaccharide preparation and method for producing the same
KR10-2003-7010649A KR20040018333A (en) 2001-02-16 2002-02-15 Oral formulations containing mucopolysaccharide for small intestine delivery and their use in the treatment circulatory disorders
EP02712385A EP1390048A2 (en) 2001-02-16 2002-02-15 Oral formulations containing mucopolysaccharide for small intestine delivery and their use in the treatment circulatory disorders
CA002438707A CA2438707A1 (en) 2001-02-16 2002-02-15 Oral formulations containing mucopolysaccharide for small intestine delivery and their use in the treatment circulatory disorders

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2001-40661 2001-02-16
JP2001040661 2001-02-16
JP2001299632 2001-09-28
JP2001-299632 2001-09-28

Publications (2)

Publication Number Publication Date
WO2002064148A2 WO2002064148A2 (en) 2002-08-22
WO2002064148A3 true WO2002064148A3 (en) 2002-11-21

Family

ID=26609566

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/001299 Ceased WO2002064148A2 (en) 2001-02-16 2002-02-15 Oral formulations containing mucopolysaccharide for small intestine delivery and their use in the treatment circulatory disorders

Country Status (5)

Country Link
EP (1) EP1390048A2 (en)
JP (1) JP2004525110A (en)
KR (1) KR20040018333A (en)
CA (1) CA2438707A1 (en)
WO (1) WO2002064148A2 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
US7357891B2 (en) 2001-10-12 2008-04-15 Monosol Rx, Llc Process for making an ingestible film
US10285910B2 (en) 2001-10-12 2019-05-14 Aquestive Therapeutics, Inc. Sublingual and buccal film compositions
US20110033542A1 (en) 2009-08-07 2011-02-10 Monosol Rx, Llc Sublingual and buccal film compositions
US8765167B2 (en) 2001-10-12 2014-07-01 Monosol Rx, Llc Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US20190328679A1 (en) 2001-10-12 2019-10-31 Aquestive Therapeutics, Inc. Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US8603514B2 (en) 2002-04-11 2013-12-10 Monosol Rx, Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
US11207805B2 (en) 2001-10-12 2021-12-28 Aquestive Therapeutics, Inc. Process for manufacturing a resulting pharmaceutical film
DE10332160A1 (en) 2003-07-15 2005-02-03 Röhm GmbH & Co. KG Multiparticulate dosage form containing mucoadhesively formulated peptide or protein active substances, and a method for producing the dosage form
ES2426445T3 (en) * 2006-04-07 2013-10-23 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
CN107096012A (en) 2008-05-07 2017-08-29 诺和诺德股份有限公司 Composition of peptide and preparation method thereof
JP4630931B2 (en) * 2009-03-10 2011-02-09 有限会社エヌアール・ラボラトリー Gastrointestinal soluble dosage form
WO2011120033A1 (en) 2010-03-26 2011-09-29 Merrion Research Iii Limited Pharmaceutical compositions of selective factor xa inhibitors for oral administration
IT1400232B1 (en) * 2010-05-07 2013-05-24 Advance Holdings Ltd PHARMACEUTICAL COMPOSITION TOPICAL COMPARING EPARIN
KR101005981B1 (en) * 2010-08-13 2011-01-05 이흥재 Bicycle that drives the front wheels by moving the handle back and forth
US9149959B2 (en) 2010-10-22 2015-10-06 Monosol Rx, Llc Manufacturing of small film strips
CA2819108A1 (en) * 2010-12-15 2012-06-21 Merrion Research Iii Limited Pharmaceutical compositions of selective factor xa inhibitors for oral administration
EP2661273A4 (en) 2011-01-07 2014-06-04 Merrion Res Iii Ltd Pharmaceutical compositions of iron for oral administration
EP2834635A4 (en) * 2012-04-03 2015-09-02 Smiths Medical Asd Inc HEPARINE LOAD AGENT COMPOSITIONS AND ASSOCIATED METHODS
ITMI20130682A1 (en) * 2013-04-24 2014-10-25 Giuliani Spa FORMS OF DOSAGE FOR ORAL ADMINISTRATION OF ACTIVE SUBSTANCES
US10265384B2 (en) 2015-01-29 2019-04-23 Novo Nordisk A/S Tablets comprising GLP-1 agonist and enteric coating
US11273131B2 (en) 2016-05-05 2022-03-15 Aquestive Therapeutics, Inc. Pharmaceutical compositions with enhanced permeation
US11191737B2 (en) 2016-05-05 2021-12-07 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine compositions
US12433850B2 (en) 2016-05-05 2025-10-07 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine and prodrug compositions
US12427121B2 (en) 2016-05-05 2025-09-30 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine compositions
WO2023076281A1 (en) 2021-10-25 2023-05-04 Aquestive Therapeutics, Inc. Oral and nasal compositions and methods of treatment
CN117304356A (en) * 2023-08-22 2023-12-29 重庆望业药物研究有限公司 Crystalline form A of polysulfonic acid mucopolysaccharide and its preparation method and application

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0497162A1 (en) * 1991-01-30 1992-08-05 ALFA WASSERMANN S.p.A. Pharmaceutical compositions containing orally absorbable glycosaminoglycans
WO1997005903A2 (en) * 1995-08-08 1997-02-20 Danbiosyst Uk Limited Composition for enhanced uptake of polar drugs from the colon
WO2000032172A1 (en) * 1998-11-27 2000-06-08 Kanji Takada An oral formulation for gastrointestinal drug delivery
WO2000050012A1 (en) * 1999-02-22 2000-08-31 Elan Corporation, Plc Solid oral dosage form containing an enhancer
US20010024658A1 (en) * 1999-08-17 2001-09-27 Feng-Jing Chen Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0497162A1 (en) * 1991-01-30 1992-08-05 ALFA WASSERMANN S.p.A. Pharmaceutical compositions containing orally absorbable glycosaminoglycans
WO1997005903A2 (en) * 1995-08-08 1997-02-20 Danbiosyst Uk Limited Composition for enhanced uptake of polar drugs from the colon
WO2000032172A1 (en) * 1998-11-27 2000-06-08 Kanji Takada An oral formulation for gastrointestinal drug delivery
WO2000050012A1 (en) * 1999-02-22 2000-08-31 Elan Corporation, Plc Solid oral dosage form containing an enhancer
US20010024658A1 (en) * 1999-08-17 2001-09-27 Feng-Jing Chen Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin

Also Published As

Publication number Publication date
WO2002064148A2 (en) 2002-08-22
JP2004525110A (en) 2004-08-19
EP1390048A2 (en) 2004-02-25
KR20040018333A (en) 2004-03-03
CA2438707A1 (en) 2002-08-22

Similar Documents

Publication Publication Date Title
WO2002064148A3 (en) Oral formulations containing mucopolysaccharide for small intestine delivery and their use in the treatment circulatory disorders
CA2419404A1 (en) Compositions and methods for treating sexual dysfunction
ATE326867T1 (en) COMPOSITION CONTAINING FREE AMINO ACID
JPS6245536A (en) Choline esters as absorption enhancer for supplying drug through mucosa of nose, mouth, tongue and vagina
RU98111594A (en) PHARMACEUTICAL COMPOSITIONS INCLUDING FLURBIPROFEN
KR920000324A (en) Essential Fatty Acid Treatment
EP0252290A2 (en) Pharmaceutical compositions containing levodopa methyl ester, preparation and therapeutic applications thereof
JPS6245535A (en) Acylcarnitines as absorption enhancer for supplying drug through mucosa of nose, mouth, tongue and vagina
AU2002309038B2 (en) Compositions for transmucosal administration containing coenzyme Q as the active ingredient
WO2003072111A3 (en) Omega-3 fatty acids or omega-3 phosphatidylcholine in the treatment of depression
WO2002102743A3 (en) DEUTERATED N-SUBSTITUTED AND α-SUBSTITUTED DIPHENYLALKOXY ACETIC ACID AMINO ALKYL ESTERS AND MEDICAMENTS CONTAINING THESE COMPOUNDS
ZA971134B (en) Multifunctional fat absorption and blood cholesterol reducing formulation.
AU4898890A (en) A system for the controlled release of active agents and a process for its preparation
JP2001010977A (en) Oral composition
GEP20053610B (en) Pediatric Formulation Of Gatifloxacin
Guillot et al. Intestinal absorption of medium chain fatty acids: in vivo studies in pigs devoid of exocrine pancreatic secretion
EP0965340B1 (en) Dermatologic preparation
RU2005113980A (en) STRENGTHENING ALCOHOL METABOLISM
DE60112584D1 (en) Process for the preparation of a liquid dosage unit and kit
FI89004C (en) ANVAENDNING AV TILLSATSMEDEL FOER OEKNING AV ABSORPTIONSHASTIGHETEN AV LAEKEMEDEL I ORALA LAEKEMEDELSPREPARAT
US11813237B2 (en) Creatine, its derivatives, compositions and methods of use thereof
JP3534793B2 (en) Glycyrrhizinate rectal formulation
JPS6322524A (en) Analgesic cyclic and bridged cyclic somatostatin analog
JP2003342186A (en) Oral liquid composition for rhinitis
JP2810730B2 (en) Motilin preparation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2002712385

Country of ref document: EP

Ref document number: 2002232203

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1020037010649

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2002563941

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 028050622

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2438707

Country of ref document: CA

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2002712385

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020037010649

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 2002712385

Country of ref document: EP